Eli Lilly priced the company’s acute migraine treatment Reyvow at $640 for a pack of eight pills.
Tokyo-based Daiichi Sankyo’s ESAX-DN Phase III trial of esaxerenone met the primary endpoint in diabetic nephropathy.
Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
Sanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
LevLane Advertising was named agency of record by innovative health technology company Vital USA Inc.
Abbott’s Afinion HbA1c Dx assay was launched as the only rapid point-of-care test cleared by the U.S. Food and Drug Administration to aid healthcare professionals in the diagnosis of diabetes and the assessment of patients’ risk of developing the condition.
Flow, a medical device company, launched a medication-free treatment for depression comprising a brain stimulation headset and therapy app.
The U.S. FDA approved AbbVie Inc.’s Skyrizi as a treatment for plaque psoriasis at a time when the company’s blockbuster psoriasis medicine Humira faces patent pressures.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Teva Pharmaceutical Industries Ltd. announced the exclusive launch of a generic version of Reyataz (atazanavir) capsules in the U.S.
